<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05126992</url>
  </required_header>
  <id_info>
    <org_study_id>D8111R00006</org_study_id>
    <nct_id>NCT05126992</nct_id>
  </id_info>
  <brief_title>EU Secondary Data Post-Authorisation Safety Study of AZD1222</brief_title>
  <acronym>D8111R00006</acronym>
  <official_title>A Post-authorisation/Post-marketing Observational Study to Evaluate the Association Between Exposure to AZD1222 and Safety Concerns Using Existing Secondary Health Data Sources</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>RTI Health Solutions</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      A study based on electronic heath records will evaluate the incidence and relative risk of&#xD;
      safety concerns and adverse events of special interest (AESIs) following immunisation by&#xD;
      AZD1222 in the real-world setting.&#xD;
&#xD;
      A cohort and a self-controlled case series desings will be used.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This retrospective study based on electronic heath records will evaluate the incidence and&#xD;
      relative risk of safety concerns and adverse events of special interest (AESIs) following&#xD;
      immunisation by AZD1222 in the real-world setting. The primary study objectives are to (1)&#xD;
      describe baseline characteristics of all individuals who receive at least one dose of AZD1222&#xD;
      over the study period; (2) describe, among subjects who receive a first dose of AZD1222, the&#xD;
      timing and type of second dose of any COVID-19 vaccine over the study period; (3) describe&#xD;
      the incidence of prespecified AESIs in subjects who have received at least one dose of&#xD;
      AZD1222 and in matched unvaccinated subjects; and (4) estimate any increased risk of&#xD;
      prespecified AESIs following vaccination with AZD1222 using study retrospective cohort and&#xD;
      self-controlled risk interval designs. Secondary objectives are identical to the primary,&#xD;
      although focused on specific populations considered to have missing information, specifically&#xD;
      (a) women who are pregnant or breastfeeding, (b) immunocompromised patients, (b) frail&#xD;
      patients with certain comorbidities, (c) patients with autoimmune or inflammatory disorders,&#xD;
      and (d) patients who, at cohort entry, had recently received a number of selected vaccines to&#xD;
      prevent diseases other than COVID-19. A cohort and a self-controlled case series desings will&#xD;
      be used.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 22, 2021</start_date>
  <completion_date type="Anticipated">April 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 15, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events of special interest</measure>
    <time_frame>up to 365 days</time_frame>
    <description>several AESIs</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">5200000</enrollment>
  <condition>COVID-19, Vaccine Adverse Events of Special Interest</condition>
  <arm_group>
    <arm_group_label>AZD1222</arm_group_label>
    <description>at least one dose of AZD1222</description>
  </arm_group>
  <arm_group>
    <arm_group_label>comparator</arm_group_label>
    <description>non vaccinated</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AZD1222</intervention_name>
    <description>Covid-19 AstraZeneca Vaccine</description>
    <arm_group_label>AZD1222</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will include subjects who are exposed to the AZD1222 vaccine and&#xD;
        concurrent subjects who have not received any SARS-CoV-2 vaccine, who will serve as&#xD;
        comparators.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have at least 12 months of data available before cohort entry&#xD;
&#xD;
          -  Have no record of vaccination with any SARS-CoV-2 vaccine on or before the date of&#xD;
             cohort entry&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>AstraZeneca Clinical Study Information Center</last_name>
    <phone>1-877-240-9479</phone>
    <email>information.center@astrazeneca.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>FISABIO - Foundation for the Promotion of Health and Biomedical Research of Valencia Region</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 9, 2021</study_first_submitted>
  <study_first_submitted_qc>November 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2021</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AZD1222</keyword>
  <keyword>ChAdOx1nCoV-19</keyword>
  <keyword>Vaccine Adverse Events of Special Interest</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <study_docs>
    <study_doc>
      <doc_id>EUPAS Register</doc_id>
      <doc_type>URL</doc_type>
      <doc_url>http://www.encepp.eu/encepp/viewResource.htm?id=43565</doc_url>
      <doc_comment>EUPAS Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

